Dr. Kenneth DeSantes, MD
Claim this profileUniversity of Wisconsin Hospital and Clinics
Studies Aplastic Anemia
Studies Tumors
8 reported clinical trials
17 drugs studied
Affiliated Hospitals
Clinical Trials Kenneth DeSantes, MD is currently running
IST + BMT
for Aplastic Anemia
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia). This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA. The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms. This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.
Recruiting2 awards Phase 3
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
More about Kenneth DeSantes, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Kenneth DeSantes, MD has experience with
- Methotrexate
- Rabbit Anti-Thymocyte Globulin (ATG)
- Horse Anti-Thymocyte Globulin (ATG)
- Cyclophosphamide
- Fludarabine
- Low-dose Total Body Irradiation (TBI)
Breakdown of trials Kenneth DeSantes, MD has run
Aplastic Anemia
Tumors
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kenneth DeSantes, MD specialize in?
Kenneth DeSantes, MD focuses on Aplastic Anemia and Tumors. In particular, much of their work with Aplastic Anemia has involved treating patients, or patients who are undergoing treatment.
Is Kenneth DeSantes, MD currently recruiting for clinical trials?
Yes, Kenneth DeSantes, MD is currently recruiting for 6 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Kenneth DeSantes, MD has studied deeply?
Yes, Kenneth DeSantes, MD has studied treatments such as Methotrexate, Rabbit Anti-Thymocyte Globulin (ATG), Horse Anti-Thymocyte Globulin (ATG).
What is the best way to schedule an appointment with Kenneth DeSantes, MD?
Apply for one of the trials that Kenneth DeSantes, MD is conducting.
What is the office address of Kenneth DeSantes, MD?
The office of Kenneth DeSantes, MD is located at: University of Wisconsin Hospital and Clinics, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Hospital and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.